Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the selection of patients for EGFR-targeted therapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gattenlöhner, S., Etschmann, B., Kunzmann, V., Thalheimer, A., Hack, M., Kleber, G., Einsele, H., Germer, C., Müller-Hermelink, H. -K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hindawi Publishing Corporation 2009
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837901/
https://ncbi.nlm.nih.gov/pubmed/20300583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/831626
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge